Literature DB >> 3932078

Linear pharmacokinetics of intravenous ergotamine tartrate.

J J Ibraheem, L Paalzow, P Tfelt-Hansen.   

Abstract

Ergotamine tartrate 0.5, 0.25 and 0.125 mg was administered i.v. to 6 volunteers in a cross-over study. Its pharmacokinetic characteristics were evaluated from plasma concentration-time data determined by HPLC. The clearance and volume of distribution were independent of the dose. The ratio between blood and plasma ergotamine concentrations in 4 subjects ranged from 0.41-0.67, indicating the lack of binding to blood cells. Ergotamine was found to be a high clearance drug, average 2.21/min/70 kg body wt. suggesting extrahepatic clearance. A possible transient decrease in liver blood flow caused by ergotamine did not seem to affect the linearity of its kinetics.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3932078     DOI: 10.1007/bf00547370

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  General and regional haemodynamic effects of intravenous ergotamine in man.

Authors:  P Tfelt-Hansen; I L Kanstrup; N J Christensen; K Winkler
Journal:  Clin Sci (Lond)       Date:  1983-12       Impact factor: 6.124

3.  Determination of ergot alkaloids in plasma by high-performance liquid chromatography and fluorescence detection.

Authors:  P O Edlund
Journal:  J Chromatogr       Date:  1981-11-13

4.  Bioavailability of dihydroergotamine in man.

Authors:  P J Little; G L Jennings; H Skews; A Bobik
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

5.  Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers.

Authors:  J J Ibraheem; L Paalzow; P Tfelt-Hansen
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

6.  Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man.

Authors:  W H Aellig; E Nüesch
Journal:  Int J Clin Pharmacol Biopharm       Date:  1977-03

7.  Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers.

Authors:  J J Ibraheem; L Paalzow; P Tfelt-Hansen
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Optimal routes of administration of ergotamine tartrate in cluster headache patients. A pharmacokinetic study.

Authors:  K Ekbom; A E Krabbe; G Paalzow; L Paalzow; P Tfelt-Hansen; E Waldenlind
Journal:  Cephalalgia       Date:  1983-03       Impact factor: 6.292

  8 in total
  1 in total

Review 1.  Extrahepatic metabolism of drugs in humans.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.